Hematologic Oncology Update

Featuring a presentation by Dr Matthew Matasar, including the following topics:
Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (0:00)
Clinician Survey Results Regarding First-Line Treatment of DLBCL (11:41)
Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL (16:01)
Clinician Survey Results Regarding the Use of Monoclonal and Bispecific Antibodies for R/R DLBCL (28:47)
Evidence-Based Incorporation of Antibody-Drug Conjugates (ADCs) into the Management of R/R DLBCL (34:34)
Clinician Survey Results Regarding the Use of ADCs for R/R DLBCL (46:31)
Discussion of Questions from the Community (50:20)

CME information and select publications

Featuring an interview with Dr Matthew Lunning, including the following topics:
A woman in her late 70s with non-GCB diffuse large B-cell lymphoma receives pola-R-CHP — Ann LaCasce, MD, MMSc (0:00)
CNS prophylaxis in non-Hodgkin lymphoma (7:58)

CME information and select publications

Featuring perspectives from Dr Lindsey Roeker, including the following topics:
Case: A man in his mid 60s with TP53-aberrant chronic lymphocytic leukemia (CLL) with extensive marrow infiltration receives first-line venetoclax/obinutuzumab and experiences an excellent response (0:00)
Case: A man in his late 70s with small lymphocytic lymphoma (SLL) and cardiovascular comorbidities requiring verapamil and anticoagulation receives acalabrutinib/venetoclax; Case: A man in his early 80s with SLL receives zanubrutinib/sonrotoclax as part of the CELESTIAL-TNCLL trial (14:46)
Case: A man in his late 70s with progressive CLL worsening after a skiing injury receives acalabrutinib/venetoclax as part of the MAJIC trial (22:37)

CME information and select publications

Featuring perspectives from Dr Lindsey Roeker, including the following topics:
Consensus Approach to optimizing front-line treatment (0:00)
Emerging role of sonrotoclax (8:39)
Bruton tyrosine kinase inhibitor monotherapy for older patients; discontinuation (14:48)
Evolving role of minimal residual disease assessment (19:16)

CME information and select publications

Featuring perspectives from Dr Spencer Bachow, Dr Bhavana (Tina) Bhatnagar, Dr Jennifer Crombie, Dr Manali Kamdar and Ms Alexandra Lynch, co-moderated by Dr Bachow and Dr Bhatnagar, including the following topics:
Introduction and Overview of Bispecific Antibodies in the Clinic (0:00)
Current and Future Role of Bispecific Antibodies in Non-Hodgkin Lymphoma — Dr Kamdar (15:58)
Case: A man in his early 60s with diffuse large B-cell lymphoma (DLBCL) receives glofitamab (42:40)
Case: A woman in her early 80s with follicular lymphoma (FL) receives mosunetuzumab (51:50)
Mitigation and Management of Cytokine Release Syndrome (CRS) and Other Toxicities Associated with Bispecific Antibodies — Dr Crombie (1:00:39)
Case: A woman in her early 80s with DLBCL receives glofitamab (1:18:50)
Case: A woman in her early 70s with FL receives epcoritamab (1:26:38)
Outpatient CRS Management in B-Cell Lymphomas — Ms Lynch (1:29:28)
Case: A woman in her late 40s with FL receives epcoritamab (1:38:33)
Case: A man in his early 70s with mantle cell lymphoma receives mosunetuzumab (1:46:26)

CME information and select publications